- ￥3483
- CompTech
- A338
- 美国
- 2025年07月11日
11 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格：
1.0 ml/vial
存储温度： -70oC or below. Minimize freeze/thaw cycles.
来源：Normal human serum (shown by certified tests to be negativefor HBsAg and for antibodies to HCV, HIV-1 and HIV-II).
存储溶液：10 mM sodium phosphate, 145 mM NaCl, pH 7.3
参考文献：Abramson, N., Alper, C.A., Lachmann P.J., Rosen, F.S. and Jandl, J.H. (1971) Deficiency of C3 inactivator in man. J. Immunol 107:19-27. Davis, A.E.III, Davis, J.S.IV, Robson, A.R., Osofsky,S.G. Colten, H.R., Rosen, F.S. and Alper, C.A. (1977) Homozygous C3 deficiency: detection of C3 by radioimmunoassay. Clin. Immunol. Immunopathol. 8:543-550. Dodds, A.W. and Sim, R.B. editors (1997) Complement. A Practical Approach (ISBN 019963539) Oxford University Press, Oxford. Laursen, S.B., Thiel, S., Teisner, B., Holmskov, U., Wang, Y., Sim, R.B., and Jensenius, J.C. (1994) Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c. Immunology. 81:648-54. Morgan, B.P. ed. (2000) Complement Methods and Protocols. (ISBN 0-89603-654-5) Humana Press, Inc., Totowa, New Jersey. Nilsson, S.C., Trouw, L.A., Renault, N., Miteva, M.A., Genel, F., Zelazko, M., Marquart, H., Muller, K., Sjöholm, A.G., Truedsson, L., Villoutreix, B.O., and Blom, A.M. (2009) Genetic, molecular and functional analyses of complement factor I deficiency. Eur J Immunol. 39:310-323. Pangburn, M.K., Schreiber, R.D. and Muler-Eberhard, H.J. (1977) Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J. Exp. Med. 146:257-270. Pangburn, M.K., Müller-Eberhard, H.J. (1980) Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med. 152:1102-1114.
官网链接：http://www.complementtech.com/product-description/Factor%20I-Dpl.htm
商品关键词：Factor I-Dpl,A338,CompTech
简单描述：Normal human serum was depleted of factor I by immunoaffinity chromatography. The product is tested for the absence of factor I by double immunodiffusion. Factor I is a regulator of complement activation (Pangburn, M.K., et al. (1977)). Factor I-Dpl is still capable of activating all three pathways of complement if metal ions are added. Activation of the alternative pathway is spontaneous and occurs in normal blood, in factor I deficient individuals and in Factor I-Dpl serum. Our depleted serum is stored with 0.1 mM EDTA to inhibit spontaneous activation. Upon the addition of magnesium ions spontaneous activation produces fluid phase C3b due to alternative pathway tick-over (Pangburn, M.K., Müller-Eberhard, H.J. (1980)). In normal human blood or serum this C3b would be rapidly inactivated to iC3b, by factors H and I (Pangburn, M.K., et al. (1977); (Laursen, S.B. et al. (1994)), however, in the absence of factor I, C3b remains as C3b. This C3b binds factor B and factor B is activated by factor D forming the C3b,Bb complex and the free Ba fragment. Because factor H is present in Factor I-Dpl Bb is rapidly decayed off the C3b,Bb complex. The free C3b then binds another factor B and the process repeats itself until little or no factor B remains. In factor I-deficient individuals their factor B levels are very low and they exhibit low or very low C3 levels (Davis, A.E.III, et al. (1977); Nilsson, S.C., et al. (2009)). Individuals with factor I deficiencies are susceptible to recurrent bacterial infections and exhibit little or no alternative pathway activity (Abramson, N. et al. (1971); Nilsson, S.C., et al. (2009)).Factor I-Dpl is certified to possess a functional alternative pathway for complement activation only if factor I or a controlling factor with a function similar to that of factor I is added prior to the addition of metal ions (specifically Mg++). Full reconstitution requires addition of 34 µg factor I/mL serum. It is also tested for and certified to contain functional classical pathway indicating that all other complement components necessary for classical and alternative pathway activation are present except for factor I (Morgan, B.P. (2000); Dodds, A.W. and Sim, R.B. (1997)).
Concentration: >50 mg protein/mL (see Certificate of Analysis for actual conc.)
Form: Frozen liquid
Activity: >80% versus NHS standard after reconstitution with factor I
Purity: No factor I detectable by immunodiffusion
Preservative: None, 0.22 µm filtered
Physical Characteristics : Factor I-Dpl is supplied as a clear, straw-colored liquid containing all proteins of normal human serum except complement factor I.
Function: Factor I-Dpl serum is not functionally deficient in either alternative or classical pathway activity, but without factor I the feedback loop of the alternative pathway will spontaneously activate within a few minutes if magnesium is added prior to addition of factor I or a factor I-like control protein. We verify that fully functional alternative and classical pathways are restored after addition of 34 µg/mL factor I (CompTech #A138). It is tested for classical pathway activity with assays using antibody-sensitized sheep erythrocytes (EA, CompTech #B200) and for alternative pathway function using rabbit erythrocytes (Er, CompTech #B300). The Certificate of Analysis provided with each lot gives a description of the assays and specific titers for the depleted and reconstituted sera compared to normal human serum. Lectin pathway activity is not routinely tested or certified, but it would be expected to be active in this depleted serum.
Assays: Because the complement system is still intact in Factor I-Dpl it is possible, to use this depleted serum to titer factor I or factor I-like proteins. If sufficient factor I or factor I-like activity is added back to stabilize the alternative pathway for the duration of the experiment then the alternative pathway can be assayed. An APH50 value is determined for Factor I-Dpl + factor I. The factor I should be titered to be equivalent to between 0 and 34 µg factor I/mL in the original undiluted serum plus 5 mM MgEGTA (CompTech #B106). After a preincubation period (10 to 30 min at 37oC) a titer of the remaining alternative pathway activity or of factor B activity can be performed. In assays where insufficient factor I was present factor B will be consumed during the preincubation period and this will result in loss of alternative pathway activity. The remaining alternative pathway activity may be determined by measuring the amount needed to lyse 50% of 1.5 x 107 rabbit erythrocytes (CompTech #B300)) when incubated in GVBo (CompTech #B103) containing a final concentration of 5 mM MgEGTA (CompTech #B106) in a total volume of 100 µL for 30 min at 37oC.A more specific assay of factor I activity may also be performed. Radiolabeled C3b, biotinylated C3b or fluorescently tagged C3b may be added to the serum and SDS-PAGE used to detect cleavage of the labeled C3b alpha chain into two fragments characteristic of iC3b.
Precautions/Toxicity/Hazards: The source is human serum, therefore precautions appropriate for handling any blood-derived product must be used even though the source was shown by certified tests to be negative for HBsAg and for antibodies to HCV, HIV-1 and HIV-II.
Hazard Code: B WGK Germany 3MSDS is available upon request.
官网链接: www.annoron.com
办公电话: 010-56256916
官方售后: 400-965-8633
企业QQ: 3198592576、3212874516
来源：Normal human serum (shown by certified tests to be negativefor HBsAg and for antibodies to HCV, HIV-1 and HIV-II).
存储溶液：10 mM sodium phosphate, 145 mM NaCl, pH 7.3
参考文献：Abramson, N., Alper, C.A., Lachmann P.J., Rosen, F.S. and Jandl, J.H. (1971) Deficiency of C3 inactivator in man. J. Immunol 107:19-27. Davis, A.E.III, Davis, J.S.IV, Robson, A.R., Osofsky,S.G. Colten, H.R., Rosen, F.S. and Alper, C.A. (1977) Homozygous C3 deficiency: detection of C3 by radioimmunoassay. Clin. Immunol. Immunopathol. 8:543-550. Dodds, A.W. and Sim, R.B. editors (1997) Complement. A Practical Approach (ISBN 019963539) Oxford University Press, Oxford. Laursen, S.B., Thiel, S., Teisner, B., Holmskov, U., Wang, Y., Sim, R.B., and Jensenius, J.C. (1994) Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c. Immunology. 81:648-54. Morgan, B.P. ed. (2000) Complement Methods and Protocols. (ISBN 0-89603-654-5) Humana Press, Inc., Totowa, New Jersey. Nilsson, S.C., Trouw, L.A., Renault, N., Miteva, M.A., Genel, F., Zelazko, M., Marquart, H., Muller, K., Sjöholm, A.G., Truedsson, L., Villoutreix, B.O., and Blom, A.M. (2009) Genetic, molecular and functional analyses of complement factor I deficiency. Eur J Immunol. 39:310-323. Pangburn, M.K., Schreiber, R.D. and Muler-Eberhard, H.J. (1977) Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J. Exp. Med. 146:257-270. Pangburn, M.K., Müller-Eberhard, H.J. (1980) Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med. 152:1102-1114.
官网链接：http://www.complementtech.com/product-description/Factor%20I-Dpl.htm
商品关键词：Factor I-Dpl,A338,CompTech
简单描述：Normal human serum was depleted of factor I by immunoaffinity chromatography. The product is tested for the absence of factor I by double immunodiffusion. Factor I is a regulator of complement activation (Pangburn, M.K., et al. (1977)). Factor I-Dpl is still capable of activating all three pathways of complement if metal ions are added. Activation of the alternative pathway is spontaneous and occurs in normal blood, in factor I deficient individuals and in Factor I-Dpl serum. Our depleted serum is stored with 0.1 mM EDTA to inhibit spontaneous activation. Upon the addition of magnesium ions spontaneous activation produces fluid phase C3b due to alternative pathway tick-over (Pangburn, M.K., Müller-Eberhard, H.J. (1980)). In normal human blood or serum this C3b would be rapidly inactivated to iC3b, by factors H and I (Pangburn, M.K., et al. (1977); (Laursen, S.B. et al. (1994)), however, in the absence of factor I, C3b remains as C3b. This C3b binds factor B and factor B is activated by factor D forming the C3b,Bb complex and the free Ba fragment. Because factor H is present in Factor I-Dpl Bb is rapidly decayed off the C3b,Bb complex. The free C3b then binds another factor B and the process repeats itself until little or no factor B remains. In factor I-deficient individuals their factor B levels are very low and they exhibit low or very low C3 levels (Davis, A.E.III, et al. (1977); Nilsson, S.C., et al. (2009)). Individuals with factor I deficiencies are susceptible to recurrent bacterial infections and exhibit little or no alternative pathway activity (Abramson, N. et al. (1971); Nilsson, S.C., et al. (2009)).Factor I-Dpl is certified to possess a functional alternative pathway for complement activation only if factor I or a controlling factor with a function similar to that of factor I is added prior to the addition of metal ions (specifically Mg++). Full reconstitution requires addition of 34 µg factor I/mL serum. It is also tested for and certified to contain functional classical pathway indicating that all other complement components necessary for classical and alternative pathway activation are present except for factor I (Morgan, B.P. (2000); Dodds, A.W. and Sim, R.B. (1997)).
Concentration: >50 mg protein/mL (see Certificate of Analysis for actual conc.)
Form: Frozen liquid
Activity: >80% versus NHS standard after reconstitution with factor I
Purity: No factor I detectable by immunodiffusion
Preservative: None, 0.22 µm filtered
Physical Characteristics : Factor I-Dpl is supplied as a clear, straw-colored liquid containing all proteins of normal human serum except complement factor I.
Function: Factor I-Dpl serum is not functionally deficient in either alternative or classical pathway activity, but without factor I the feedback loop of the alternative pathway will spontaneously activate within a few minutes if magnesium is added prior to addition of factor I or a factor I-like control protein. We verify that fully functional alternative and classical pathways are restored after addition of 34 µg/mL factor I (CompTech #A138). It is tested for classical pathway activity with assays using antibody-sensitized sheep erythrocytes (EA, CompTech #B200) and for alternative pathway function using rabbit erythrocytes (Er, CompTech #B300). The Certificate of Analysis provided with each lot gives a description of the assays and specific titers for the depleted and reconstituted sera compared to normal human serum. Lectin pathway activity is not routinely tested or certified, but it would be expected to be active in this depleted serum.
Assays: Because the complement system is still intact in Factor I-Dpl it is possible, to use this depleted serum to titer factor I or factor I-like proteins. If sufficient factor I or factor I-like activity is added back to stabilize the alternative pathway for the duration of the experiment then the alternative pathway can be assayed. An APH50 value is determined for Factor I-Dpl + factor I. The factor I should be titered to be equivalent to between 0 and 34 µg factor I/mL in the original undiluted serum plus 5 mM MgEGTA (CompTech #B106). After a preincubation period (10 to 30 min at 37oC) a titer of the remaining alternative pathway activity or of factor B activity can be performed. In assays where insufficient factor I was present factor B will be consumed during the preincubation period and this will result in loss of alternative pathway activity. The remaining alternative pathway activity may be determined by measuring the amount needed to lyse 50% of 1.5 x 107 rabbit erythrocytes (CompTech #B300)) when incubated in GVBo (CompTech #B103) containing a final concentration of 5 mM MgEGTA (CompTech #B106) in a total volume of 100 µL for 30 min at 37oC.A more specific assay of factor I activity may also be performed. Radiolabeled C3b, biotinylated C3b or fluorescently tagged C3b may be added to the serum and SDS-PAGE used to detect cleavage of the labeled C3b alpha chain into two fragments characteristic of iC3b.
Precautions/Toxicity/Hazards: The source is human serum, therefore precautions appropriate for handling any blood-derived product must be used even though the source was shown by certified tests to be negative for HBsAg and for antibodies to HCV, HIV-1 and HIV-II.
Hazard Code: B WGK Germany 3MSDS is available upon request.
官网链接: www.annoron.com
办公电话: 010-56256916
官方售后: 400-965-8633
企业QQ: 3198592576、3212874516
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
光因素系环境因素之一。光对生物生活的作用可以从光量及光质的性质和日照时间来考虑。所谓光量的性质即亮度（照度），而光质的性质即波长组成。光量的性质是由太阳高度和介质的透光度决定的。光通过植物群落上层叶片到达群落下层，故群落下层的波谱分布移向短波。水深引起的波谱分布变化是显著的，通常，因清彻的水对长波光吸收很快，故达到深层的光大部分都是短波光。这种变化影响着藻类的垂直分布。就日照时间来说，从年累计看纬度对它引起的差异几乎是没有的，但从地理位置上看，高纬度地区季节变化对它影响却很大，在植物
对射线的吸收，即使量是相等的，但因射线质的不同，所以在生物效应上也是不同的，这就需要用一个系数加以修正，此称为射线质量系数，以Q或QF表示。在实际的射线防护方面已被采用。对估计人体被辐射的射线量当量（Sv或rem），应是生物学效应的射线量，而历来对吸收的射线量都是乘以RBE值，但根据ICRP的建议（1962），现在一般都乘以射线质量系数Q。正像对各射线都假定有一定的RBE值而计算的危险度过大那样，而对射线能赋与（LET）的关系而来确定的（表）。
寻找居住在某个区域的种群从一个世代到另一个世代的数量变化的主要原因以及主要原因作用下的发育阶段的方法。莫里斯（ R． F． Moris， 1959）指出，这种变化的主因（ key-factor）是对种群起作用的各种死亡原因（迁出、迁入，繁殖能力的变化也包括在内）中对每代的作用强度有很大变化的原因，一般是由一个或几个这样的原因决定着昆虫个体数目的巨大变大。莫里斯（ 1963）对野外种群获得的再生产曲线，如在两轴取对数，则大致可得直线，以此经验事实为基础，考虑预期变化主因
技术资料暂无技术资料 索取技术资料
Factor I-Dpl
￥3483
